Topiramate in migraine prevention

Area of Science:

• Neurology
• Pharmacology

Background:

• Migraine is a common neurological disorder impacting quality of life.
• Effective prophylactic treatments are crucial for managing migraine frequency and severity.

Purpose of the Study:

• To evaluate the efficacy and tolerability of topiramate for migraine prophylaxis.
• To establish topiramate as a first-line treatment option for migraine prevention.

Main Methods:

• Two multicenter, randomized, double-blind, placebo-controlled trials were conducted.
• Adult participants received either 100 mg or 200 mg of topiramate daily.
• Efficacy was assessed by reductions in migraine headache frequency and use of acute medications.

Main Results:

• Topiramate significantly reduced migraine frequency, number of migraine days, and acute medication use.
• No significant efficacy difference was noted between 100 mg and 200 mg daily doses.
• Common adverse events included paresthesia, fatigue, decreased appetite, nausea, diarrhea, weight decrease, and taste perversion.

Conclusions:

• Topiramate is an effective first-line migraine preventive medication.
• The recommended initial target dose for most patients is 100 mg daily.
• Topiramate is a preferred option for patients concerned about weight gain or with coexisting epilepsy.